Traws Pharma (TRAW) CMO awarded 108,854 stock options at $1.60

Rhea-AI Filing Summary

Traws Pharma, Inc. reported that Chief Medical Officer Robert Redfield received a grant of stock options covering 108,854 shares of common stock. These options have an exercise price of $1.6000 per share and were awarded under the company’s 2021 Incentive Compensation Plan.

The options will vest 100% on the first anniversary of the March 8, 2026 grant date, and expire on March 8, 2036. Following this award, Redfield holds options for 108,854 underlying shares, reflecting a compensation-related acquisition rather than an open‑market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Redfield Robert

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	108,854	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 108,854 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Redfield Robert

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTON PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		108,854		03/08/2027(1)	03/08/2036	Common Stock	108,854	$0	108,854	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ Robert Redfield	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Traws Pharma (TRAW) report for Robert Redfield?

Traws Pharma reported that Chief Medical Officer Robert Redfield received stock options for 108,854 shares. The options were granted as compensation, giving him the right to buy common stock at a set price if they vest and are later exercised.

What are the key terms of Robert Redfield’s new Traws Pharma stock options?

Redfield’s options cover 108,854 shares of common stock at an exercise price of $1.6000 per share. They were granted under the 2021 Incentive Compensation Plan and represent a right to buy shares, not an immediate purchase or sale.

When do Robert Redfield’s Traws Pharma stock options vest and expire?

The stock options will vest 100% on the first anniversary of the March 8, 2026 grant date. They carry an expiration date of March 8, 2036, after which any unexercised options will lapse and can no longer be used.

Is Robert Redfield’s Form 4 transaction a market buy or sell of Traws Pharma shares?

The transaction is a grant of stock options, not a market buy or sell. It reflects a compensation-related award giving Redfield the right to acquire shares in the future, rather than an immediate trade in Traws Pharma’s stock.

How many Traws Pharma shares can Robert Redfield acquire from this option grant?

The grant allows Robert Redfield to acquire up to 108,854 shares of Traws Pharma common stock. He can exercise these options at $1.6000 per share after they vest, subject to the plan’s terms and the options’ 2036 expiration date.